X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (133) 133
humans (96) 96
selective sglt2 inhibitor (81) 81
dapagliflozin (77) 77
diabetes mellitus, type 2 - drug therapy (76) 76
pharmacology & pharmacy (72) 72
diabetes (70) 70
double-blind (63) 63
type 2 diabetes (63) 63
sodium-glucose transporter 2 - antagonists & inhibitors (61) 61
glucose (59) 59
selective inhibitor (59) 59
animals (58) 58
hypoglycemic agents - therapeutic use (55) 55
glucosides - therapeutic use (51) 51
inadequate glycemic control (49) 49
male (49) 49
hyperglycemia (40) 40
endocrinology & metabolism (38) 38
type-2 diabetes-mellitus (37) 37
glucosides - pharmacology (36) 36
sglt2 inhibitor (33) 33
sodium-glucose transporter 2 - metabolism (33) 33
dextrose (32) 32
glycemic control (32) 32
hypoglycemic agents - pharmacology (32) 32
female (31) 31
mellitus (30) 30
diabetes mellitus (29) 29
insulin (28) 28
metformin (27) 27
glucosides - adverse effects (26) 26
kidney - metabolism (26) 26
pharmacokinetics (26) 26
sglt2 (26) 26
sodium (26) 26
type 2 diabetes mellitus (26) 26
glucose - metabolism (25) 25
hypoglycemic agents - adverse effects (25) 25
middle aged (25) 25
diabetes mellitus, type 2 - metabolism (24) 24
rats (24) 24
sglt2 inhibitors (22) 22
benzhydryl compounds (21) 21
benzhydryl compounds - therapeutic use (21) 21
glucosides - pharmacokinetics (21) 21
hypoglycemic agents - pharmacokinetics (21) 21
benzhydryl compounds - pharmacology (20) 20
empagliflozin (20) 20
glucose cotransporter 2 (20) 20
safety (20) 20
blood glucose - metabolism (19) 19
treatment outcome (19) 19
canagliflozin (18) 18
care and treatment (18) 18
drug therapy (18) 18
glucose metabolism (18) 18
hypoglycemic agents (18) 18
blood glucose - drug effects (17) 17
diabetes mellitus, type 2 - blood (17) 17
aged (16) 16
hypoglycemic agents - administration & dosage (16) 16
na+/glucose cotransporter (16) 16
placebo-controlled trial (16) 16
thiophenes - therapeutic use (16) 16
adult (15) 15
blood-pressure (15) 15
internal medicine (15) 15
kidney - drug effects (15) 15
mice (15) 15
type-2 (15) 15
analysis (14) 14
benzhydryl compounds - adverse effects (14) 14
blood pressure (14) 14
body-weight (14) 14
chemistry, medicinal (14) 14
clinical trials (14) 14
drug therapy, combination (14) 14
glucosides - administration & dosage (14) 14
ipragliflozin (14) 14
blood sugar (13) 13
efficacy (13) 13
insulin resistance (13) 13
medicine & public health (13) 13
pharmacology (13) 13
rodents (13) 13
sodium-glucose transport proteins - antagonists & inhibitors (13) 13
add-on (12) 12
diabetes mellitus, type 2 - complications (12) 12
diabetes mellitus, type 2 - physiopathology (12) 12
dose-response relationship, drug (12) 12
inhibitors (12) 12
insulin-resistance (12) 12
oxidative stress (12) 12
selective inhibitor ipragliflozin (12) 12
urology & nephrology (12) 12
clinical trials as topic (11) 11
cotransporter 2 inhibitor (11) 11
diabetes therapy (11) 11
dosage and administration (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Organic Process Research and Development, ISSN 1083-6160, 04/2018, Volume 22, Issue 4, pp. 467 - 488
Gliflozins are an important class of prescription drugs used to treat type II diabetes. They reduce blood sugar levels by targeting the sodium-glucose... 
DIABETES-MELLITUS | SELECTIVE C-ARYLATION | TOFOGLIFLOZIN | COTRANSPORTER 2 INHIBITORS | 1,2-ANHYDRO SUGARS | PRACTICAL STEREOSELECTIVE-SYNTHESIS | CHEMISTRY, ORGANIC | GLUCOSE-TRANSPORT | CROSS-COUPLING APPROACH | SCALABLE SYNTHESIS | CHEMISTRY, APPLIED | DISCOVERY
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2012, Volume 92, Issue 2, pp. 158 - 169
Journal Article
KIDNEY INTERNATIONAL, ISSN 0085-2538, 03/2011, Volume 79, pp. S14 - S19
The physiological and pathological handling of glucose via sodium-glucose cotransporter-2 (SGLT2) in the kidneys has been evolving, and SGLT2 inhibitors have... 
phlorizin | GLYCEMIC CONTROL | RENAL GLUCOSURIA | SGLT2 | dapagliflozin | NA+-GLUCOSE COTRANSPORTER | SELECTIVE INHIBITOR | ANTIDIABETIC AGENTS | EMERGING TARGET | UROLOGY & NEPHROLOGY | FATTY RATS | diabetes | insulin resistance | TYPE-2 DIABETES-MELLITUS | REMOGLIFLOZIN ETABONATE | NA+/GLUCOSE COTRANSPORTER | glucosuria
Journal Article
Chemistry – A European Journal, ISSN 0947-6539, 02/2018, Volume 24, Issue 12, pp. 2832 - 2836
Inhibition of the sodium‐glucose co‐transporters (SGLT1 and SGLT2) is a validated strategy to address the increasing prevalence of type II diabetes mellitus .... 
carbohydrates | selective glycosylation | bioiosteres | diabetes | fluorine | DESIGN | MECHANISM | GLUCOSE-GALACTOSE MALABSORPTION | MELLITUS | CHEMISTRY, MULTIDISCIPLINARY | MEDICINAL CHEMISTRY | INACTIVATION | INTERFACE | EXPLORATION | BIOLOGY | NA+/GLUCOSE COTRANSPORTER | Fluorides | Glucose | Diabetes | Dextrose | Sodium | Fluorine | Diabetes mellitus | Reabsorption | Glycosylation | Inhibition | Nuclei | Index Medicus
Journal Article
Chemistry – A European Journal, ISSN 0947-6539, 02/2018, Volume 24, Issue 12, pp. 2791 - 2791
The Type II sodium–glucose co‐transporter (SGLT2, grey), located in the proximal tubule (gold) consists of a large transmembrane protein and is responsible for... 
carbohydrates | selective glycosylation | bioiosteres | diabetes | fluorine
Journal Article
American Journal of Hypertension, ISSN 0895-7061, 02/2018, Volume 31, Issue 3, pp. 274 - 280
Journal Article
Heterocycles, ISSN 0385-5414, 2016, Volume 92, Issue 9, pp. 1599 - 1613
The development of an efficient and practical process for the preparation of Sergliflozin etabonate (1), a prodrug of a novel selective low-affinity... 
O-Glycosylation Selective | Ethoxycarbonylation | Low-Affinity Na+-Dependent Glucose Cotransporter (SGLT2) Inhibitor | CHEMISTRY, ORGANIC | Sergliflozin Etabonate
Journal Article
Current Topics in Medicinal Chemistry, ISSN 1568-0266, 2010, Volume 10, Issue 4, pp. 411 - 418
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 03/2012, Volume 156, Issue 6, pp. 405 - 415
Background: Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2, may improve glycemic control with a lower dose of insulin and attenuate the... 
Primary funding source: astrazeneca and bristol-myers squibb | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | THERAPY | DOUBLE-BLIND | RISK | GLIMEPIRIDE | INADEQUATE GLYCEMIC CONTROL | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2014, Volume 16, Issue 2, pp. 124 - 136
AimsDapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), has been shown to improve glycaemic control, stabilize insulin dosing and... 
type 2 diabetes | insulin | inhibitor | SGLT2 | randomized trial | glycaemic control | renal glucose handling | Type 2 diabetes | Randomized trial | Renal glucose handling | Insulin | SGLT2 inhibitor | Glycaemic control | METFORMIN | SELECTIVE SGLT2 INHIBITOR | ADD-ON | MELLITUS | INADEQUATE GLYCEMIC CONTROL | BODY-WEIGHT | PHARMACOKINETICS | CANAGLIFLOZIN | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | WEIGHT-GAIN | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Weight Loss - drug effects | Genital Diseases, Female - chemically induced | Metformin - adverse effects | Benzhydryl Compounds - adverse effects | Urinary Tract Infections - chemically induced | Aged, 80 and over | Adult | Female | Glucosides - therapeutic use | Drug Therapy, Combination | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Genital Diseases, Male - chemically induced | Insulin - administration & dosage | Treatment Outcome | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Complications and side effects | Glucose metabolism | Care and treatment | Analysis | Urinary tract infections | Glucose | Dextrose | Infections | Diabetes | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article